Department of Reproductive Medical Research Center, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Research Department, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, China.
PLoS One. 2017 Apr 19;12(4):e0175501. doi: 10.1371/journal.pone.0175501. eCollection 2017.
Atosiban is administered to women undergoing in vitro fertilization-embryo transfer (IVF-ET) to improve pregnancy outcomes. However, the results of this treatment were controversial. We conducted this meta-analysis to investigate whether atosiban improves pregnancy outcomes in the women undergoing in vitro fertilization (IVF).
Databases of PubMed, EMBASE, Web of Science, China BioMedicine, and Google Scholar were systematically searched. Meta-analyses were performed to investigate whether atosiban improves pregnancy outcomes in the women undergoing IVF.
Our results showed that atosiban was associated with higher implantation (OR = 1.63, 95% CI: 1.17-2.27; P = 0.004) and clinical pregnancy (OR = 1.84, 95% CI: 1.31-2.57; P < 0.001) rates. However, atosiban showed no significant association with the miscarriage, live birth, multiple pregnancy or ectopic pregnancy rates. When a further subgroup analysis was performed in the women undergoing repeated implantation failure (RIF), implantation (OR = 1.93, 95% CI: 1.45-2.57; P < 0.001), clinical pregnancy (OR = 2.48, 95% CI: 1.70-3.64; P <0.001) and the live birth (OR = 2.89, 95% CI: 1.78-4.67; P < 0.001) rates were significantly higher in the case group. Nevertheless, no significant difference was detected in the miscarriage and multiple pregnancy rates between the case and control groups.
Atosiban may be more appropriate for women undergoing RIF and play only a limited role in improving pregnancy outcomes in the general population of women undergoing IVF. These conclusions should be verified in large and well-designed studies.
阿托西班被用于接受体外受精-胚胎移植（IVF-ET）的女性，以改善妊娠结局。然而，该治疗方法的结果存在争议。我们进行了这项荟萃分析，以调查阿托西班是否能改善接受体外受精（IVF）的女性的妊娠结局。
系统检索了 PubMed、EMBASE、Web of Science、中国生物医学文献数据库和 Google Scholar 数据库。进行荟萃分析以调查阿托西班是否能改善接受 IVF 的女性的妊娠结局。
我们的结果表明，阿托西班与更高的着床率（OR = 1.63，95%CI：1.17-2.27；P = 0.004）和临床妊娠率（OR = 1.84，95%CI：1.31-2.57；P < 0.001）相关。然而，阿托西班与流产率、活产率、多胎妊娠率或异位妊娠率无关。当对反复着床失败（RIF）的女性进行进一步的亚组分析时，着床率（OR = 1.93，95%CI：1.45-2.57；P < 0.001）、临床妊娠率（OR = 2.48，95%CI：1.70-3.64；P < 0.001）和活产率（OR = 2.89，95%CI：1.78-4.67；P < 0.001）在病例组中显著更高。然而，病例组和对照组在流产率和多胎妊娠率方面没有显著差异。
阿托西班可能更适合接受 RIF 的女性，而在接受 IVF 的一般女性中，对改善妊娠结局的作用有限。这些结论需要在大型和精心设计的研究中得到验证。
